NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
1,981,872
1,598,951
1,146,290
475,598
18,662
Cost of revenue
902,639
902,639
-
-
-
Gross profit
1,079,233
696,312
-
-
-
Operating expenses
Research development
1,235,278
1,235,278
2,534,508
747,027
113,842
Selling general and administrative
488,691
488,691
298,358
145,290
34,417
Total operating expenses
1,723,969
1,341,048
2,832,866
892,317
148,259
Operating income or loss
-644,736
-644,736
-1,686,576
-416,719
-129,597
Interest expense
19,880
19,880
21,127
15,145
12,188
Total other income/expenses net
10,969
10,969
-8,197
12,591
9,003
Income before tax
-653,647
-653,647
-1,714,536
-418,259
-132,694
Income tax expense
4,292
4,292
29,215
-
-
Income from continuing operations
-657,939
-657,939
-1,743,751
-418,259
-132,694
Net income
-657,939
-657,939
-1,743,751
-418,259
-132,694
Net income available to common shareholders
-657,939
-657,939
-1,743,751
-418,259
-132,694
Basic EPS
-
-8.42
-23.44
-7.27
-5.51
Diluted EPS
-
-8.42
-23.44
-7.27
-5.51
Basic average shares
-
78,183
74,400
57,554
24,100
Diluted average shares
-
78,183
74,400
57,554
24,100
EBITDA
-
-633,767
-1,686,576
-416,719
-129,597